Current approach in the diagnosis and management of panuveitis

Indian Journal of Ophthalmology

Volumn 58, Issue 1, 2010, Pages 45-54

  Bansal, Reema ^a   Gupta, Vishali ^a   Gupta, Amod ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diagnosis; Management; Panuveitis

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HUMAN; METHODOLOGY; OPTICAL COHERENCE TOMOGRAPHY; PROGNOSIS; UVEITIS; VITRECTOMY;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PANUVEITIS; PROGNOSIS; TOMOGRAPHY, OPTICAL COHERENCE; VITRECTOMY;

EID: 73849085978     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.58471     Document Type: Conference Paper

References (102)

1. Rao NA, Buddi R. Treatment of uveitis with immunosuppressive agents. Indian J Ophthalmol 1993;41:107-113
2. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular Inflammatory disease. Am J Ophthalmol 1987;103:234-5.
3. Singh R, Gupta V, Gupta A. Pattern of Uveitis in a Referral Eye Clinic in North India. Ind J Ophthalmol 2004;52:121-125
4. Chan SM, Hudson M, Weis E. Anterior and intermediate uveitis cases referred to tertiary centre in Alberta. Can J Ophthalmol 2007;42:860-864
5. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin 2005;45:1-13.
6. Biswas J, Narain S, Das D, Ganesh SK. Pattern of uveitis in a referral uveitis clinic in India. Int Ophthalmol 1996;20:223-228 (Pubitemid 27173635)
7. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516
8. Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis. Ocul Immunol Inflamm 2008;16:1-2.
9. Finamor LP, Muccioli C, Belfort R Jr. Imaging techniques in the diagnosis and management of uveitis. Int Ophthalmol Clin 2005;45:31-40.
10. Bouchenaki N, Cimino L, Auer C, Tao Tran V, Herbort CP. Assessment and classification of choroidal vasculitis in posterior uveitis using indocyanine green angiography. Klin Monatsbl Augenheilkd 2002;219:243-249
11. Ciardella AP, Borodoker N, Costa DL, Huang SJ, Cunningham ET Jr, Slakter JS. Imaging the posterior segment in uveitis. Ophthalmol Clin North Am 2002;15:281-96.
12. Wada S, Kohno T, Yanagihara N, Hirabayashi M, Tabuchi H, Shiraki K, et al. Ultrasound biomicroscopic study of ciliary body changes in the post-treatment phase of Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2002;86:1374-9.
13. Roters S, Szurman P, Engels BF, Bartz-Schmidt KU, krieglstein GK. Ultrasound biomicroscopy in chronic ocular hypotony: its impact on diagnosis and management. Retina 2002;22:581-8.
14. Gupta V, Gupta P, Singh R, Dogra MR, Gupta A. Spectral-Domain Cirrus High-Definition Optical Coherence Tomography Is Better than Time-Domain Stratus Optical Coherence Tomography for Evaluation of Macular Pathologic Features in Uveitis. Am J Ophthalmol 2008;145:1018-1022
15. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet's disease, the Silk Road and HLA-B51: Historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
16. Van Gelder RN. Applications of the polymerase chain reaction to diagnosis of ophthalmic disease. Surv Ophthalmol 2001;46:248-58.
17. Biswas J, Rao NA. Management of intraocular in-fiammation: In: Retina, Ryan SJ, editor. Vol.2. St. Louis: CV Mosby; 1989. p. 139-146, 1989.
18. Akova YA, Foster CS. Cataract surgery in patients with sarcoidosisassociated uveitis. Ophthalmology 1994;101:473-9.
19. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for Sarcoidassociated panuveitis. Ophthalmology 1999;106:111-118
20. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet 1989;1:1093-6.
21. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322:281-5. (Pubitemid 20046329)
22. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huongdu LT, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335-339
23. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6.
24. Lim L, Suhler EB, Smith JR. Biologic therapies for Inflammatory eye disease. Clin Experiment Ophthalmol 2006;34:365-74.
25. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. infliximab therapy for the treatment of refractory ocular Inflammatory disease. Arch Ophthalmol 2007;125:895-900.
26. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, et al. Long-term Efficacy of infliximab in refractory posterior uveitis of Behcet's disease: A 24-month follow-up study. Rheumatology (Oxford) 2007;46:1161-4.
27. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivett i-Pezzi P. infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007;51:191-6.
28. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sightt hreatening uveitis in Behcet's disease. Eye 2007;21:824-5.
29. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter noncomparative interventional case series. Ophthalmology 2005;112:764-70.
30. Plskova J, Greiner K, Forrester JV. Interferon-a as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55-61.
31. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008;19:535-540
32. Ahn JK, Chung H, Yu HG. Vitrectomy for persistent panuveitis in Behcet's disease. Ocul Immunol Inflamm 2005;13:447-453
33. Van Gelder RN, Kaplan HJ. Diagnostic and therapeutic vitrectomy for uveitis. In: Retina, Ryan SJ, editors. 3rd ed. Philadelphia: Mosby; 2001. p. 2264-9.
34. Soheilian M, Aletaha M, Yazdani S, Dehghan MH, Peyman GA. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm 2006;14:91-98
35. Wakabayashi T, Morimura Y, Miyamoto Y, Okada AA. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm 2003;11:277-86.
36. Islam SM, Tabbara KF. Causes of uveitis at the eye center in Saudi Arabia: A retrospective review. Ophthalmic Epidemiol 2002;9:239-49.
37. Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of anti-tubercular therapy in uveitis with latent/manifest tuberculosis. Am J Ophthamol 2008;146:772-779
38. Itty S, Bakri SJ, Pulido JS, Herman DC, Faia LJ, Tufty GT, et al. Initial results of QuantiFERON-TB Gold testing in patients with uveitis. Eye 2009;23:904-909
39. Brogden P, Varma A, Backhouse O. Interferon-gamma assay in tuberculous uveitis. Br J Ophthalmol 2008;92:582-583
40. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-92.
41. Kondo I, Yamagata K, Yamaki K, Sakuragi S. [Analysis of the candidate antigen for Harada's disease]. Nippon Ganka Gakkai Zasshi.Acta Societatis Ophthalmologicae Japonicae 1994;98:596. 603.
42. Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 1996;8:799-803.
43. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 1996;80:1002-8.
44. Nomura S, Matsuzaki T, Ozaki Y, Yamaoka M, Yoshimura C, Katsura K, et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 1998;91:3616-22. (Pubitemid 28225727)
45. Numaga J, Matsuki K, Tokunaga K, Juji T, Mochizuki M. Analysis of human leukocyte antigen HLA-DR beta amino acid sequence in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci 1991;32:1958-61.
46. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada's disease by PCR-RFLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol 1994;78:223-6.
47. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H. Complete association of the HLA-DRB1*04 and-DQB1*04 alleles with Vogt-Koyanagi-Harada's disease. Human Immunol 1994;39:169-76.
48. Shindo Y, Ohno S, Nakamura S, Onoe K, Inoko H. A significant association of HLA-DPB1&0501 with Vogt-Koyanagi-Harada's disease results from a linkage disequilibrium with the primarily associated allele, DRB1&0405. Tissue Antigens 1996;47:344-5.
49. Weisz JM, Holland GN, Roer LN, Park MS, Yuge AJ, Moorthy RS, et al. Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and-DR4 in Hispanic patients living in southern California. Ophthalmology 1995;102:1012-5.
50. Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 1980;90:69-75.
51. Sugiura S. [Some observations on uveitis in Japan, with special reference to Vogt-Koyanagi-Harada and Behçet diseases (author.s transl)]. Nippon Ganka Gakkai Zasshi 1976;80:1285-326.
52. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international comittee on nomenclature. Am J Ophthalmol 2001;131:647-52.
53. Tabbara KF, Chavis PS, Freemann WR. Vogt-Koyanagi-Harada syndrome in children compared to adults. Acta Ophthalmol Scand 1998;76:723-6.
54. Herbort CP, Mantovani A, Bouchenaki N. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: Angiographic signs and utility in patient follow-up. Int Ophthalmol 2007;27:173-182
55. Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2007;15:381-387
56. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2001;131:599-606.
57. Rathinam SR, Vijayalakshmi P, Namperumalsamy P, Nozik RA, Cunningham ET jr. Vogt-Koyanagi-Harada syndrome in children. Ocul Immunol Inflamm 1998;6:155-161.
58. Forster DJ, Green RL, Rao NA. Unilateral manifestation of the Vogt-Koyanagi-Harada syndrome in a 7-year-old child. Am J Ophthalmol 1991;111:380.2.
59. Weber SW, Kazdan JJ. The Vogt-Koyanagi-Harada syndrome in children. J Pediatr Ophthalmol 1977;14:96-9.
60. Kimura SJ, Hogan MJ. Uveitis in children: Analysis of 274 cases. Trans Am Ophthalmol Soc 1964;62:173-92.
61. Cross AG. Uveitis in children. Trans Ophthalmol Soc UK 1965;85:409-19.
62. Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing Patterns in uveitis of childhood. Ophthalmology 1996;103:375-83.
63. Pivett i-Pezzi P. Uveitis in children. Eur J Ophthalmol 1996;6:293-8.
64. Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm 2000;8:251-61.
65. Nussenblatt RB, Palestine AB, Whitcup SM, Craven L. Sympathetic Ophthalmia. Uveitis: Fundamentals and Clinical Practice. St Louis, MO: CV Mosby; 1995. p. 299-311.
66. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the United Kingdom and Republic of Ireland. Br J Ophthalmol 2000;84:259-263
67. Rao NA, Forster DJ, Spalton DJ. Sympathetic ophthalmia. In: Podos SM, Yanoff M, editors. The Uvea Uveitis and Intraocular Neoplasms. Vol.2, Chapter 8. USA: Mosby-Wolfe; 1995. p. 810-813.
68. Nussenblatt RB. Sympathetic Ophthalmia. In: Nussenblatt RB, Whitcup SM, editors. Uveitis Fundamentals and Clinical Practice. 3rd ed. Chapter 22. USA: Elsevier; 2004. p. 311-23.
69. Gupta V, Gupta A, Dogra MR. Posterior Sympathetic Ophthalmia: A single centre long-term study of 40 patients from North India. Eye 2008;22:1459-1464
70. Nussenblatt RB. Uveitis in Behçet's disease. Int Rev Immunol 1997;14:67-79.
71. Yates PA, Michelson JB. Behçet's disease. Int Ophthalmol Clin 2006;46:209-33.
72. Okada AA. Behçet's disease: general concepts and recent advances. Curr Opin Ophthalmol 2006;17:551-6.
73. Atmaca LS. Fundus changes associated with Behçet's disease. Graefe's Arch Clin Exp Ophthalmol 1989;227:340-4.
74. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet's disease: An analysis of 880 patients. Am J Ophthalmol 2004;138:373-80.
75. Pazarli H, Ozyazgan Y, Bahcecioglu H, Yazici H, Hattat N, Yurdakul S, et al. Ocular involvement in Behcet's syndrome in Turkey. In: Lehner T, Barnes CG, editors. Behcet's Disease, vol.103. Royal Society of Medicine Services, London: 1986. p. 267-8.
76. Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behcet's disease. Semin Arthritis Rheum 1979;8:223-60.
77. Zafirakis P, Foster CS. Adamantiades-Behcet disease. In: Foster CS, Vitale AT, editors. Diagnosis and Treatment of Uveitis. Philadelphia: Saunders; 2002. p. 632-52.
78. Zierhut M, Stübiger N, Deuter CME, Kötter I. Behcet's disease. In: Pleyer, U., Mondino, B. (Eds.), Uveitis and Immunological Disorders. Springer; Berlin, Heidelberg: 2005. p. 173-200.
79. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
80. Lee S. Diagnostic criteria of Behcet's disease: Problems and suggestions. Yonsei Med J 1997;38:365.9.
81. Mason RM, Barnes CG. Behcet's syndrome with arthritis. Ann Rheum Dis 1969;28:95-103.
82. O'Duffy JD. Suggested criteria for diagnosis of Behc-et's Disease. J Rheumatol 1974;1:18.
83. Dilsen N, Konice M, Aral O. Our diagnostic criteria of Behcet's Disease.an overview, recent advances in Behcet's Disease. London Royal Society of Medicine Services. Int Congr Sympos Series 1986;103:177-80.
84. Mizushima Y. Revised diagnostic criteria for Behcet's disease in 1987. Ryumachi 1988;28:66-70.
85. Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of cyclosporine therapy for Behcet's disease. Arthritis Rheum 1985;28:671-9.
86. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporine A in ocular Behcet's disease. Doc Ophthalmol 2002;105:301-12.
87. Süllü Y, Oge I, Erkan D, Aritürk N, Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol Scand 1998;76:96-9.
88. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322:281-5. (Pubitemid 20046329)
89. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
90. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum 2005;52:2478-84.
91. Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35.
92. Ganesh SK, Agarwal M. Clinical and investigative profile of biopsy-proven Sarcoid uveitis in India. Ocul Immunol Inflamm 2008;16:17-22.
93. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986;102:297-301.
94. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978;86:648-55.
95. James DG, Neville E, Langley DA. Ocular sarcoidosis. Trans Ophthalmol Soc UK 1976;96:133-9.
96. James DG. Ocular sarcoidosis. Ann NY Acad Sci 1986;465:551-63.
97. Dana MR, Merayo.Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 1996;103:1846-53.
98. Rothova A, Sutt orp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular Inflammatory disease. Br J Ophthalmol 1996;80:332-6.
99. Dios E, Saornil MA, Herreras JM. Conjunctival biopsy in the diagnosis of ocular sarcoidosis. Ocul Immunol Inflamm 2001;9:59-64.
100. Das A, Chatterjee S, Bagchi SC, Gupta SK. Ocular involvement in sarcoidosis. Indian J Ophthalmol 1984;32:195-9.
101. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular Inflammatory disease. Ophthalmology 1992;99:1419-23.
102. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976;55:39-65.